UTHR Q4 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Globe and Mail, The
Chairperson and Chief Executive Officer — Dr. Martine Rothblatt President and Chief Operating Officer — Michael Benkowitz Chief Financial Officer and Treasurer — James Edgemond Executive Vice President of Product Development and Xenotransplantation — Dr. Leigh Peterson Executive Vice President of Strategic Development — Pat Poisson Need a quote from a Motley Fool analyst? Email pr@fool.com Takeaways United Therapeutics (NASDAQ:UTHR) reported $790 million in total revenue for the fourth quarter, a 7% increase year over year from Q4 2024. Full-year revenue -- Surpassed $3 billion for the first time, representing 11% annual growth. Tyvaso revenue -- $464 million in the fourth quarter, up 12% year over year, with 24% annual growth from Tyvaso DPI. Soft mist inhaler product launch -- Management plans to file for regulatory approval of "Tresmi" for PAH and ILD this year, with commercial launch targeted for next year. Tyvaso DPI platform enhancement -- Introduction o
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- CPRX or UTHR: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026 [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026Business Wire
- The Bull Case For United Therapeutics (UTHR) Could Change Following FDA RMAT Status For miroliverELAP [Yahoo! Finance]Yahoo! Finance
- Groundbreaking Meeting of Minds at Northwell Health's Quantum Biology Forum Unlocks New Understanding of Life's Fundamental Principles [Yahoo! Finance]Yahoo! Finance
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/20/26 - Form 4
- UTHR's page on the SEC website